Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan

British Journal of Cancer

Volumn 100, Issue 2, 2009, Pages 281-290

  Kondo, M ^a,b   Hoshi, S L ^a   Toi, M ^c  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Breast cancer; Chemoprevention; Cost effectiveness; Prophylaxis; Raloxifene; Tamoxifen

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; CANCER PREVENTION; CANCER RISK; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG SUBSTITUTION; ECONOMIC EVALUATION; ENDOMETRIUM CANCER; FEMALE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH STATUS; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; JAPANESE; LUNG CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; JAPAN; MARKOV CHAINS; MIDDLE AGED; NEOPLASM INVASIVENESS; POSTMENOPAUSE; RALOXIFENE; RISK FACTORS; TAMOXIFEN;

EID: 58749107116     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604869     Document Type: Article

References (45)

1. Armstrong K, Chen TM, Albert D, Randall TC, Schwartz JS (2001) Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98: 996-1003
2. Bevers TB (2007) The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Cancer Netw 5: 719-724
3. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65: 125-134
4. Chau Q, Cantor SB, Caramel E, Hicks M, Kurtin D, Grover T, Elting LS (2003) Cost-effectiveness of the bird's nest filter for preventing pulmonary embolism among patients with malignant brain tumors and deep venous thrombosis of the lower extremities. Support Care Cancer 11: 795-799
5. Chen Z, Wu AH, Gauderman WJ, Bernstein L, Ma H, Pike MC, Ursin G (2004) Does mammographic density reflect ethnic differences in breast cancer incidence rates? Am J Epidemiol 159: 140-147
6. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators (2007) Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99: 272-282
7. Cykert S, Phifer N, Hansen C (2004) Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 104: 433-442
8. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, de Haes JC, Collette HJ, Hendriks JH, van der Maas PJ (1991) Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 49: 531-537
9. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647
10. Drummond M, Pang F (2001) Transferability of economic evaluation results. In Economic Evaluation in Health Care: Merging Theory with Practice Drummond M and McGuire A (eds). Oxford: Oxford University Press
11. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18: 3302-3317
12. Eckermann SD, Martin AJ, Stockler MR, Simes RJ (2003) The benefits and costs of tamoxifen for breast cancer prevention. Aust N Z J Public Health 27: 34-40
13. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97: 1652-1662
14. Fuji T, Nakamura M, Yamada N, Kobayashi M, Yamauchi K, Nakano T (2005) Health economic analysis of prevention of deep vein thrombosis - an application of pharmacoeconomics. Sogo Rinsho 54: 2988-2997
15. Fukawa T (1998) Ageing and health expenditure of the elderly. J Jpn Soc Hosp Adm 35: 109-121
16. Gail MH, Costantino JP (2001) Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 93: 334-335
17. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Bernstein L (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99(23): 1782-1792
18. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16: 979-985
19. Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI (2000) Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J 6: 169-178
20. Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR (2002) Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 20: 9-16
21. Hillner BE, Smith TJ, Desch CE (1993) Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat 25: 97-105
22. Iwata H, Saeki T (2006) Current practices in breast cancer treatment in Japan - a questionnaire survey. Jpn J Breast Cancer 21: 311-322
23. Japan Cancer Society (2007) Gankenshin no jisshi jyokyo. No.39. Tokyo: Japan Cancer Society
24. Japanese Society of Obstetrics and Gynecology (2000) Zenkoku shikyutaigan chousa seiseki. Dai 5 hou. 1989-1990 nendo shourei Tokyo: Japanese Society of Obstetrics and Gynecology
25. Kanis JA, Borgström F, Johnell O, Oden A, Sykes D, Jönsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16: 15-25
26. Kitamura S, Hasegawa Y, Suzuki S, Sasaki R, Iwata H, Wingstrand H, Thorngren KG (1998) Functional outcome after hip fracture in Japan. Clin Orthop Relat Res 348: 29-36
27. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96: 1751-1761
28. Matsuda S, Ishikawa BK (2003) Kyuuseiki nyuuiniryo shikou shindangun-bunrui wo katsuyou shita chousakenkyuu. Report of Health and Labour Sciences Research Grants (Contract No.: H13-SEISAKU-034) Tokyo: Ministry of Health, Labour and Welfare
29. Melnikow J, Kuenneth C, Helms LJ, Barnato A, Kuppermann M, Birch S, Nuovo J (2006) Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer 107: 950-958
30. Ministry of Health, Labour and Welfare (2005a) Vital statistics of Japan. Tokyo: Health & Welfare Statistics Association
31. Ministry of Health, Labour and Welfare (2005b) Kokumin iryouhi. Tokyo: Health & Welfare Statistics Association
32. Naeim A, Keeler EB (2005) Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective? Breast Cancer Res Treat 94: 95-103
33. Noe LL, Becker III RV, Gradishar WJ, Gore M, Trotter JP (1999) The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care 5: S389-S406
34. Ohkusa Y (2003) Emprical research for the critical value of expenditure per QALY. Iryo to Shakai 13: 121-130
35. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99: 283-290
36. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5): 358-366
37. Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A (2005) Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes (Lond) 29: 517-523
38. Sakuma M, Nakamura M, Nakanishi N, Miyahara Y, Tanabe N, Yamada N, Kuriyama T, Kunieda T, Sugimoto T, Nakano T, Shirato K (2004) Inferior vena cava filter is a new additional therapeutic option to reduce mortality from acute pulmonary embolism. Circ J 68: 816-821
39. Smith TJ, Hillner BE (1993) The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 11: 771-776
40. Smith TJ, Hillner BE (2000) Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol 18: 284-286
41. Trueman P, Drummond M, Hutton J (2001) Developing guidance for budget impact analysis. Pharmacoeconomics 19: 609-621
42. Ueda K, Tsukuma H, Tanaka H, Ajiki W, Oshima A (2003) Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast Cancer 10: 54-62
43. Veronesi U, Maisonneuve P, Decensi A (2007a) Tamoxifen: an enduring star. J Natl Cancer Inst 99: 258-260
44. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Italian Tamoxifen Study Group (2007b) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99: 727-737
45. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon Jr ER, Wade III JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (NSABP) (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741. Erratum in: JAMA 296:2926, JAMA 298:973